Inhibitors of the proteolytic activity of the 20S proteasome have transformed the treatment of
multiple B-cell malignancies. These agents have also been employed with success in the …

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has
encouraged application of proteasome inhibitor containing therapeutic interventions in …

Objectives: The objective of this study is to evaluate the efficacy and safety of bortezomib for
treating systemic lupus erythematosus (SLE), in patients whose disease activity could not be …

It is widely acknowledged that the aging process is linked to the accumulation of damaged
and misfolded proteins. This phenomenon is accompanied by a decrease in proteasome …

Lupus myocarditis is a serious, potentially deadly disease. When it presents as an acute or
fulminant myocarditis in a patient without an established diagnosis of lupus, lupus as an …

Abstract Purpose of Review To review progress in the field of clinical trials for SLE. Recent
Findings Treatment development for SLE has been marked by failures of many later phase …

We report a case of severe lupus myocarditis with rapid, acute deterioration to cardiogenic
shock and multiorgan failure, highlighting the importance of early identification and …

Das Krankheitsbild der Sepsis, definiert als eine lebensbedrohliche Organdysfunktion,
verursacht durch eine dysregulierte Immunantwort auf eine Infektion, stellt weltweit die …

The proteasome is a large protein complex which is responsible for the majority of protein
degradation in eukaryotes. Following FDA approval of the first proteasome inhibitor …

We need better treatments for SLE. This statement remains true despite considerable
advances that have been made over the past several decades, both in terms of the best use …